Asset Details
Do you wish to reserve the book?
Choice of antiretroviral drugs for continued treatment scale‐up in a public health approach: what more do we need to know?
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Choice of antiretroviral drugs for continued treatment scale‐up in a public health approach: what more do we need to know?
Do you wish to request the book?
Choice of antiretroviral drugs for continued treatment scale‐up in a public health approach: what more do we need to know?
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Choice of antiretroviral drugs for continued treatment scale‐up in a public health approach: what more do we need to know?
2016
Overview
Introduction There have been several important developments in antiretroviral treatment in the past two years. Randomized clinical trials have been conducted to evaluate a lower dose of efavirenz (400 mg once daily). Integrase inhibitors such as dolutegravir have been approved for first‐line treatment. A new formulation of tenofovir (alafenamide) has been developed and has shown equivalent efficacy to tenofovir in randomized trials. Two‐drug combination treatments have been evaluated in treatment‐naïve and ‐experienced patients. The novel pharmacokinetic booster cobicistat has been compared to ritonavir in terms of pharmacokinetics, efficacy and safety. The objective of this commentary is to assess recent developments in antiretroviral drug treatment to determine whether new treatments should be included in new international guidelines. Discussion The use of first‐line treatment with tenofovir and efavirenz at the standard 600 mg once‐daily dose should remain the first‐choice standard of care treatment. Evidence supporting a switch to efavirenz 400 mg once daily or integrase inhibitors is sufficient to consider these drugs as alternative first‐line options, but more data are needed on their use in pregnant women and people with TB co‐infection. The use of new formulations of tenofovir is currently too preliminary to justify immediate adoption and scale‐up across HIV programmes in low‐ and middle‐income countries. The evidence supporting use of two‐drug combinations is not considered strong enough to justify changed recommendations from use of standard triple drug combinations. Cobicistat does not offer significant safety advantages over ritonavir as a pharmacokinetic booster. Conclusions For continued scale‐up of antiretroviral treatment in low‐ and middle‐income countries, use of first‐line triple combinations including efavirenz 600 mg once daily is supported by the largest evidence base. Additional studies are underway to evaluate new treatments in key populations, and these results may justify changes to these recommendations.
Publisher
International AIDS Society,John Wiley & Sons, Inc,Wiley
Subject
Acquired immune deficiency syndrome
/ Adenine - administration & dosage
/ Adenine - analogs & derivatives
/ AIDS
/ Alkynes
/ Analysis
/ Anti-HIV Agents - therapeutic use
/ Benzoxazines - administration & dosage
/ Heterocyclic Compounds, 3-Ring - administration & dosage
/ Highly active antiretroviral therapy
/ HIV
/ HIV Infections - drug therapy
/ Human immunodeficiency virus
/ Humans
/ Oxazines
/ Phosphorous Acids - administration & dosage
